Wang Jia-xiang, Dong Rui, Liu Qiu-liang, Yang Shao-bo, Fan Yu-xia, Zhang Qian, Yang Fu-quan, Wu Peng, Yu Jie-kai, Zheng Shu
Department of Surgery, First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):265-8.
To detect and identify the potential specific serum biomarkers for diagnosis of papillary thyroid cancer.
Samples of 35 patients with papillary thyroid carcinoma, 40 patients with benign thyroid nodule and 34 healthy individuals were analyzed using the SELDI-TOF ProteinChip System and bioinfomation technology to find the differential peaks which were separated by HPLC and then further analyzed by LC-MS/MS. The protein sequences were analyzed by SEQUEST software and searched in Bioworks database.
The top six mass-to-charge ratio (M/Z) peaks with the smallest P value were 6651, 6452, 7653, 7932, 15 106 and 15 848 Da, respectively. The 6651 and 6452 Da proteins were weakly expressed in papillary thyroid carcinoma but highly expressed in benign thyroid nodules and healthy individuals. The differences had statistical significance (P < 0.01). The 7653, 7932, 15 106, 15 848 Da proteins were highly expressed in papillary thyroid carcinoma but weakly expressed in benign thyroid nodules and healthy individuals. The differences were statistically significant (P < 0.01). Combination of these six proteins, using the method of leave-one-out to make crossing detection, the specificity of discriminating papillary thyroid carcinoma and non-cancer was 88.0%, and its sensitivity was 92.5%. The 6651 and 6452 Da proteins were identified as apolipoprotein C-I and apolipoprotein C-III, respectively. The 7653 and 15 106 Da proteins were identified as the same protein-alpha-globin, and the 7932 and 15,848 Da proteins were identified as the same protein-beta-globin.
The detection of differentially expressed apolipoprotein C-I, apolipoprotein C-III, alpha-globin, and beta-globin may have utility for diagnosis of papillary thyroid carcinoma and are worthy of further investigation.
检测并鉴定用于诊断甲状腺乳头状癌的潜在特异性血清生物标志物。
采用表面增强激光解吸电离飞行时间质谱（SELDI-TOF）蛋白质芯片系统和生物信息技术，对35例甲状腺乳头状癌患者、40例甲状腺良性结节患者及34例健康个体的样本进行分析，寻找差异峰，经高效液相色谱（HPLC）分离后，再用液相色谱-串联质谱（LC-MS/MS）进一步分析。通过SEQUEST软件分析蛋白质序列，并在Bioworks数据库中进行检索。
P值最小的前六个质荷比（M/Z）峰分别为6651、6452、7653、7932、15106和15848 Da。6651和6452 Da的蛋白质在甲状腺乳头状癌中表达较弱，但在甲状腺良性结节和健康个体中高表达。差异具有统计学意义（P < 0.01）。7653、7932、15106、15848 Da的蛋白质在甲状腺乳头状癌中高表达，但在甲状腺良性结节和健康个体中表达较弱。差异具有统计学意义（P < 0.01）。将这六种蛋白质联合起来，采用留一法进行交叉检测，鉴别甲状腺乳头状癌与非癌的特异性为88.0%，敏感性为92.5%。6651和6452 Da的蛋白质分别被鉴定为载脂蛋白C-I和载脂蛋白C-III。7653和15106 Da的蛋白质被鉴定为同一种蛋白质——α-珠蛋白，7932和15848 Da的蛋白质被鉴定为同一种蛋白质——β-珠蛋白。
检测差异表达的载脂蛋白C-I、载脂蛋白C-III、α-珠蛋白和β-珠蛋白可能对甲状腺乳头状癌的诊断具有应用价值，值得进一步研究。
